Novel options for the treatment of castration-resistant prostate cancer

Carsten H. Ohlmann; Axel S. Merseburger; Henrik Suttmann; David Schilling; Lutz Trojan; Carsten Kempkensteffen; Stefan Corvin; Michael J. Mathers; Patrick J. Bastian

doi:10.1007/s00345-011-0796-7

Novel options for the treatment of castration-resistant prostate cancer

Carsten H. Ohlmann^*, Axel S. Merseburger, Henrik Suttmann, David Schilling, Lutz Trojan, Carsten Kempkensteffen, Stefan Corvin, Michael J. Mathers, Patrick J. Bastian

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Urologie

11 Zitate (Scopus)

Abstract

Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

Originalsprache	Englisch
Zeitschrift	World Journal of Urology
Jahrgang	30
Ausgabenummer	4
Seiten (von - bis)	495-503
Seitenumfang	9
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-011-0796-7
Publikationsstatus	Veröffentlicht - 08.2012

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Zugriff auf Dokument

10.1007/s00345-011-0796-7

Andere Dateien und Links

Link to publication in Scopus

Zitieren

@article{937d0f243f60445f92630bb890dd5b86,

title = "Novel options for the treatment of castration-resistant prostate cancer",

abstract = "Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.",

author = "Ohlmann, {Carsten H.} and Merseburger, {Axel S.} and Henrik Suttmann and David Schilling and Lutz Trojan and Carsten Kempkensteffen and Stefan Corvin and Mathers, {Michael J.} and Bastian, {Patrick J.}",

year = "2012",

month = aug,

doi = "10.1007/s00345-011-0796-7",

language = "English",

volume = "30",

pages = "495--503",

journal = "World Journal of Urology",

issn = "0724-4983",

number = "4",

}

TY - JOUR

T1 - Novel options for the treatment of castration-resistant prostate cancer

AU - Ohlmann, Carsten H.

AU - Merseburger, Axel S.

AU - Suttmann, Henrik

AU - Schilling, David

AU - Trojan, Lutz

AU - Kempkensteffen, Carsten

AU - Corvin, Stefan

AU - Mathers, Michael J.

AU - Bastian, Patrick J.

PY - 2012/8

Y1 - 2012/8

N2 - Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

AB - Docetaxel had been the only treatment of castration-resistant prostate cancer (CRPC) that demonstrated a survival benefit for the patients. After its approval, no considerable progress has been made for several years until cabazitaxel and abiraterone acetate demonstrated a significant survival benefit in phase III clinical trials. Apart from that several other new drugs appeared including inhibitors of the androgen receptor (MDV3100), endothelin receptor antagonists (atrasentan, zibotentan), bone-targeted drugs (denosumab, Alpharadin) and immunotherapies (sipuleucel-T) capable of improving the prognosis of patients with CRPC. Here, we review the most recent advances in the treatment of CRPC and highlight the most promising new agents currently being investigated in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84864569535&partnerID=8YFLogxK

U2 - 10.1007/s00345-011-0796-7

DO - 10.1007/s00345-011-0796-7

M3 - Scientific review articles

C2 - 22101903

AN - SCOPUS:84864569535

SN - 0724-4983

VL - 30

SP - 495

EP - 503

JO - World Journal of Urology

JF - World Journal of Urology

IS - 4

ER -

Novel options for the treatment of castration-resistant prostate cancer

Abstract

Strategische Forschungsbereiche und Zentren

UN SDGs

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Zitieren